UpdatesPlus-Acne & Rosacea - launch of a new monitoring service for dermatology

Pharma Information & Reports is pleased to announce the launch of its UpdatesPlus-Acne & Rosacea service.  To receive this 36 slide report on current Acne & Rosacea R&D, as well as an up to date pipeline and clinical timeline please contact fiona.watts@leaddiscovery.co.uk

The inaugural issue includes

• The current status of the acne/rosacea pipeline and market as well as an overview of key trials
  
• Insight into Valeant's dermatology pipeline including filing plans for WC2055 (a next generation doxycycline calcium salt) and Phase 3 entry of WC3035 (sarecycline)
• An analysis of Galderma's data on the benefit of 40mg modified release doxycycline in acne.  Note that this is the sub-antimicrobial dose in Oracea used for rosacea.  The novelty of the acne data is that efficacy is superior to a higher dose of doxycyline currently employed in acne and with reduced AEs
• Phase 3 data for Galderma's Ivermectin (CD5024) in papulopustular rosacea
• New data on early stage acne products ASC-J9 (a first in class androgen modulator from AndroScience) and SB204 (an NO donor from Novan)
• Novel data from Galderma on the efficacy of adapalene gel against atrophic scarring. We speculate that Galderma could include scarring data in a future regulatory filing for late stage adapalene/BPO combination, potentially offering a competitive advantage
  
• SkinMedica's novel product aimed at treating post-inflammatory hyperpigmentation and erythema in acne patients
• Novel tretinoin delivery technology being developed by Phosphagenics allowing deeper topical penetration with reduced erythema and dryness
  

UpdatesPlus was set up nearly 15 years ago by R&D experts and has since developed into a well respected intelligence tool spanning the immunology and dermatology spectrum. We identify breaking research, clinical trial activity, drug development news and commercial events across multiple therapy areas including psoriasis, IBD, RA and many more.  What makes us really unique is our expert analysis of this information.  This analysis is packaged in monthly reports and ad hoc alerts.